Skip to main content
Top
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

Factors associated with latent tuberculosis among asylum seekers in Switzerland: a cross-sectional study in Vaud County

Authors: Apostolos Sarivalasis, Jean-Pierre Zellweger, Mohamed Faouzi, Oscar Daher, Charlotte Deslarzes, Patrick Bodenmann

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

Screening and treatment of latent tuberculosis infection (LTBI) in asylum seekers (AS) may prevent future cases of tuberculosis. As the screening with Interferon Gamma Release Assay (IGRA) is costly, the objective of this study was to assess which factors were associated with LTBI and to define a score allowing the selection of AS with the highest risk of LTBI.

Methods

In across-sectional study, AS seekers recently arrived in Vaud County, after screening for tuberculosis at the border were offered screening for LTBI with T-SPOT.TB and questionnaire on potentially risk factors. The factors associated with LTBI were analyzed by univariate and multivariate regression.

Results

Among 393 adult AS, 98 (24.93%) had a positive IGRA response, five of them with active tuberculosis previously undetected. Six factors associated with LTBI were identified in multivariate analysis: origin, travel conditions, marital status, cough, age and prior TB exposure. Their combination leads to a robust LTBI predictive score.

Conclusions

The prevalence of LTBI and active tuberculosis in AS is high. A predictive score integrating six factors could identify the asylum seekers with the highest risk for LTBI.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, Abubakar I, Lalvani A: Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis. 2011, 11 (6): 435-444.CrossRefPubMedPubMedCentral Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, Abubakar I, Lalvani A: Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis. 2011, 11 (6): 435-444.CrossRefPubMedPubMedCentral
2.
go back to reference Moran-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM: Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis. 2010, 14 (9): 1112-1119.PubMed Moran-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM: Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis. 2010, 14 (9): 1112-1119.PubMed
3.
go back to reference Diel R, Wrighton-Smith P, Zellweger JP: Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2007, 30 (2): 321-332.CrossRef Diel R, Wrighton-Smith P, Zellweger JP: Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2007, 30 (2): 321-332.CrossRef
4.
go back to reference Dasgupta K, Menzies D: Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2005, 25 (6): 1107-1116.CrossRef Dasgupta K, Menzies D: Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2005, 25 (6): 1107-1116.CrossRef
5.
go back to reference Oxlade O, Schwartzman K, Menzies D: Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis. 2007, 11 (1): 16-26.PubMed Oxlade O, Schwartzman K, Menzies D: Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis. 2007, 11 (1): 16-26.PubMed
6.
go back to reference Meima A, de Vlas SJ: Pulmonary tuberculosis incidence in migrants. 2008, Rotterdam: Erasmus University, dept of public health Meima A, de Vlas SJ: Pulmonary tuberculosis incidence in migrants. 2008, Rotterdam: Erasmus University, dept of public health
7.
go back to reference Breuss E, Helbling P, Altpeter E, Zellweger JP: Screening and treatment for latent tuberculosis infection among asylum seekers entering Switzerland. Swiss Med Wkly. 2002, 132 (15–16): 197-200.PubMed Breuss E, Helbling P, Altpeter E, Zellweger JP: Screening and treatment for latent tuberculosis infection among asylum seekers entering Switzerland. Swiss Med Wkly. 2002, 132 (15–16): 197-200.PubMed
8.
go back to reference Pai M, Minion J, Sohn H, Zwerling A, Perkins MD: Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med. 2009, 30 (4): 701-716. viiiCrossRefPubMed Pai M, Minion J, Sohn H, Zwerling A, Perkins MD: Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med. 2009, 30 (4): 701-716. viiiCrossRefPubMed
9.
go back to reference Mulder CvDH, Huisman EM, Toumanian S, Koster BFPJ, Meijer-Veldman W, van Loenhout-Rooyackers JH, Appel M, Arend SMBM, van Leth F: Role of Quantiferon-TB Gold In-Tube in screening new immigrants for tuberculosisinfection. Eur Resp J. 2012, 10.1183/09031936.00010612. Mulder CvDH, Huisman EM, Toumanian S, Koster BFPJ, Meijer-Veldman W, van Loenhout-Rooyackers JH, Appel M, Arend SMBM, van Leth F: Role of Quantiferon-TB Gold In-Tube in screening new immigrants for tuberculosisinfection. Eur Resp J. 2012, 10.1183/09031936.00010612.
10.
go back to reference Harstad I, Heldal E, Steinshamn SL, Garasen H, Winje BA, Jacobsen GW: Screening and treatment of latent tuberculosis in a cohort of asylum seekers in Norway. Scand J Public Health. 2010, 38 (3): 275-282.CrossRefPubMed Harstad I, Heldal E, Steinshamn SL, Garasen H, Winje BA, Jacobsen GW: Screening and treatment of latent tuberculosis in a cohort of asylum seekers in Norway. Scand J Public Health. 2010, 38 (3): 275-282.CrossRefPubMed
11.
go back to reference National Institute for Health and Clinical Excellence: NICE clinical Guideline 117, National Collaborative Center for Clinical Excellence. Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011, London National Institute for Health and Clinical Excellence: NICE clinical Guideline 117, National Collaborative Center for Clinical Excellence. Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011, London
12.
go back to reference Winje BA, Oftung F, Korsvold GE, Mannsaker T, Jeppesen AS, Harstad I, Heier BT, Heldal E: Screening for tuberculosis infection among newly arrived asylum seekers: comparison of QuantiFERONTB Gold with tuberculin skin test. BMC Infect Dis. 2008, 8: 65-CrossRefPubMedPubMedCentral Winje BA, Oftung F, Korsvold GE, Mannsaker T, Jeppesen AS, Harstad I, Heier BT, Heldal E: Screening for tuberculosis infection among newly arrived asylum seekers: comparison of QuantiFERONTB Gold with tuberculin skin test. BMC Infect Dis. 2008, 8: 65-CrossRefPubMedPubMedCentral
13.
go back to reference Hardy AB, Varma R, Collyns T, Moffitt SJ, Mullarkey C, Watson JP: Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax. 2010, 65 (2): 178-180.CrossRefPubMed Hardy AB, Varma R, Collyns T, Moffitt SJ, Mullarkey C, Watson JP: Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax. 2010, 65 (2): 178-180.CrossRefPubMed
14.
go back to reference Ricks PM, Cain KP, Oeltmann JE, Steve Kammerer J, Moonan PK: Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005–2009. PLoS One. 2011, 6 (11): e27405-CrossRefPubMedPubMedCentral Ricks PM, Cain KP, Oeltmann JE, Steve Kammerer J, Moonan PK: Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005–2009. PLoS One. 2011, 6 (11): e27405-CrossRefPubMedPubMedCentral
15.
go back to reference Lienhardt C, Fielding K, Sillah JS, et al: Investigation of the risk factors for tuberculosis: a case–control study in three countries in West Africa. Int J Epidemiol. 2005, 34: 914-923.CrossRefPubMed Lienhardt C, Fielding K, Sillah JS, et al: Investigation of the risk factors for tuberculosis: a case–control study in three countries in West Africa. Int J Epidemiol. 2005, 34: 914-923.CrossRefPubMed
16.
go back to reference Chiang CY, Slama K, Enarson DA: Associations between tobacco and tuberculosis. Int J Tuberc Lung Dis. 2007, 11 (3): 258-262.PubMed Chiang CY, Slama K, Enarson DA: Associations between tobacco and tuberculosis. Int J Tuberc Lung Dis. 2007, 11 (3): 258-262.PubMed
Metadata
Title
Factors associated with latent tuberculosis among asylum seekers in Switzerland: a cross-sectional study in Vaud County
Authors
Apostolos Sarivalasis
Jean-Pierre Zellweger
Mohamed Faouzi
Oscar Daher
Charlotte Deslarzes
Patrick Bodenmann
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-285

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.